Altered B cell signalling in autoimmunity

Nature Reviews Immunology

Volumn 17, Issue 7, 2017, Pages 421-436

  Rawlings, David J ^a,b   Metzler, Genita ^a,b   Wray Dutra, Michelle ^a,b   Jackson, Shaun W ^a,b  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; CD40 LIGAND; INTERLEUKIN 21; INTERLEUKIN 6; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

AUTOIMMUNITY; B LYMPHOCYTE; CELL MATURATION; CELL SHAPE; CELL TRANSFORMATION; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; HUMAN; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 85017246695     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2017.24     Document Type: Review

References (188)

1. Deng, Y. & Tsao, B. P. Advances in lupus genetics and epigenetics. Curr. Opin. Rheumatol. 26, 482-492 (2014).
2. Niewold, T. B. Advances in lupus genetics. Curr. Opin. Rheumatol. 27, 440-447 (2015).
3. Yarwood, A., Huizinga, T. W. & Worthington, J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford) 55, 199-209 (2016).
4. Parkes, M., Cortes, A., van Heel, D. A. & Brown, M. A. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat. Rev. Genet. 14, 661-673 (2013).
5. Concannon, P., Rich, S. S. & Nepom, G. T. Genetics of type 1A diabetes. N. Engl. J. Med. 360, 1646-1654 (2009).
6. Jackson, S. W., Kolhatkar, N. S. & Rawlings, D. J. B cells take the front seat: dysregulated B cell signals orchestrate loss of tolerance and autoantibody production. Curr. Opin. Immunol. 33, 70-77 (2015).
7. Hardy, R. R. & Hayakawa, K. B cell development pathways. Annu. Rev. Immunol. 19, 595-621 (2001).
8. Allman, D. & Pillai, S. Peripheral B cell subsets. Curr. Opin. Immunol. 20, 149-157 (2008).
9. Lam, K. P., Kuhn, R. & Rajewsky, K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 90, 1073-1083 (1997).
10. Srinivasan, L. et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 139, 573-586 (2009).
11. Otipoby, K. L. et al. The B-cell antigen receptor integrates adaptive and innate immune signals. Proc. Natl Acad. Sci. USA 112, 12145-12150 (2015).
12. Liu, J. L., Chiles, T. C., Sen, R. J. & Rothstein, T. L. Inducible nuclear expression of NF-κB in primary B cells stimulated through the surface Ig receptor. J. Immunol. 146, 1685-1691 (1991).
13. Norvell, A., Mandik, L. & Monroe, J. G. Engagement of the antigen-receptor on immature murine B lymphocytes results in death by apoptosis. J. Immunol. 154, 4404-4413 (1995).
14. Sater, R. A., Sandel, P. C. & Monroe, J. G. B cell receptor-induced apoptosis in primary transitional murine B cells: signaling requirements and modulation by T cell help. Int. Immunol. 10, 1673-1682 (1998).
15. Meyer-Bahlburg, A., Andrews, S. F., Yu, K. O., Porcelli, S. A. & Rawlings, D. J. Characterization of a late transitional B cell population highly sensitive to BAFF-mediated homeostatic proliferation. J. Exp. Med. 205, 155-168 (2008).
16. Kenny, J. J., O'Connell, C., Sieckmann, D. G., Fischer, R. T. & Longo, D. L. Selection of antigen-specific, idiotype-positive B cells in transgenic mice expressing a rearranged M167-μ heavy chain gene. J. Exp. Med. 174, 1189-1201 (1991).
17. Zikherman, J., Parameswaran, R. & Weiss, A. Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489, 160-164 (2012).
18. Martin, F. & Kearney, J. F. Positive selection from newly formed to marginal zone B cells depends on the rate of clonal production, CD19, and btk. Immunity 12, 39-49 (2000).
19. Burn, G. L., Svensson, L., Sanchez-Blanco, C., Saini, M. & Cope, A. P. Why is PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS Lett. 585, 3689-3698 (2011).
20. Rawlings, D. J., Dai, X. & Buckner, J. H. The role of PTPN22 risk variant in the development of autoimmunity: finding common ground between mouse and human. J. Immunol. 194, 2977-2984 (2015).
21. Kyogoku, C. et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75, 504-507 (2004).
22. Bottini, N. et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36, 337-338 (2004).
23. Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330-337 (2004).
24. Habib, T. et al. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 188, 487-496 (2012).
25. Menard, L. et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J. Clin. Invest. 121, 3635-3644 (2011).
26. Rieck, M. et al. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol. 179, 4704-4710 (2007).
27. Vang, T. et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317-1319 (2005).
28. Dai, X. et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 123, 2024-2036 (2013).
29. Zhang, J. et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 43, 902-907 (2011).
30. Mackay, F. & Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol. 9, 491-502 (2009).
31. Stadanlick, J. E. et al. Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling. Nat. Immunol. 9, 1379-1387 (2008).
32. Smith, S. H. & Cancro, M. P. Cutting edge: B cell receptor signals regulate BLyS receptor levels in mature B cells and their immediate progenitors. J. Immunol. 170, 5820-5823 (2003).
33. Schweighoffer, E. et al. The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 38, 475-488 (2013).
34. Jellusova, J. et al. Context-specific BAFF-R signaling by the NF-κB and PI3K pathways. Cell Rep. 5, 1022-1035 (2013).
35. Hobeika, E. et al. CD19 and BAFF-R can signal to promote B-cell survival in the absence of Syk. EMBO J. 34, 925-939 (2015).
36. Lindsley, R. C., Thomas, M., Srivastava, B. & Allman, D. Generation of peripheral B cells occurs via two spatially and temporally distinct pathways. Blood 109, 2521-2528 (2007).
37. Cariappa, A., Chase, C., Liu, H., Russell, P. & Pillai, S. Naive recirculating B cells mature simultaneously in the spleen and bone marrow. Blood 109, 2339-2345 (2007).
38. Rowland, S. L., Leahy, K. F., Halverson, R., Torres, R. M. & Pelanda, R. BAFF receptor signaling aids the differentiation of immature B cells into transitional B cells following tonic BCR signaling. J. Immunol. 185, 4570-4581 (2010).
39. Mackay, F. et al. Mice transgenic for Baff develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 190, 1697-1710 (1999).
40. Stohl, W. et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 48, 3475-3486 (2003).
41. Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721-731 (2011).
42. Thien, M. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20, 785-798 (2004).
43. Lesley, R. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 20, 441-453 (2004).
44. Hondowicz, B. D. et al. The role of BLyS/BLyS receptors in anti-chromatin B cell regulation. Int. Immunol. 19, 465-475 (2007).
45. Rawlings, D. J., Schwartz, M. A., Jackson, S. W. & Meyer-Bahlburg, A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nat. Rev. Immunol. 12, 282-294 (2012).
46. Isnardi, I. et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29, 746-757 (2008).
47. Kuraoka, M. et al. BCR and endosomal TLR signals synergize to increase AID expression and establish central B cell tolerance. Cell Rep. 18, 1627-1635 (2017).
48. Meffre, E. The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases. Ann. NY Acad. Sci. 1246, 1-10 (2011).
49. Mills, R. E. et al. Unbiased modifier screen reveals that signal strength determines the regulatory role murine TLR9 plays in autoantibody production. J. Immunol. 194, 3675-3686 (2015).
50. Becker-Herman, S. et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J. Exp. Med. 208, 2033-2042 (2011).
51. Pala, F. et al. Lentiviral-mediated gene therapy restores B cell tolerance in Wiskott-Aldrich syndrome patients. J. Clin. Invest. 125, 3941-3951 (2015).
52. Kolhatkar, N. S. et al. Altered BCR and TLR signals promote enhanced positive selection of autoreactive transitional B cells in Wiskott-Aldrich syndrome. J. Exp. Med. 212, 1663-1677 (2015).
53. Khan, W. N. et al. Impaired B cell maturation in mice lacking Bruton's tyrosine kinase (Btk) and CD40. Int. Immunol. 9, 395-405 (1997).
54. Lesley, R., Kelly, L. M., Xu, Y. & Cyster, J. G. Naive CD4 T cells constitutively express CD40L and augment autoreactive B cell survival. Proc. Natl Acad. Sci. USA 103, 10717-10722 (2006).
55. Schwartz, M. A., Kolhatkar, N. S., Thouvenel, C., Khim, S. & Rawlings, D. J. CD4+ T cells and CD40 participate in selection and homeostasis of peripheral B cells. J. Immunol. 193, 3492-3502 (2014).
56. Castigli, E. et al. CD40-deficient mice generated by recombination-activating gene-2-deficient blastocyst complementation. Proc. Natl Acad. Sci. USA 91, 12135-12139 (1994).
57. Castigli, E., Young, F., Carossino, A. M., Alt, F. W. & Geha, R. S. CD40 expression and function in murine B cell ontogeny. Int. Immunol. 8, 405-411 (1996).
58. Kinnunen, T. et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 121, 1595-1603 (2013).
59. Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374-1377 (2003).
60. Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577-1584 (2004).
61. Huang, H., Benoist, C. & Mathis, D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis. Proc. Natl Acad. Sci. USA 107, 4658-4663 (2010).
62. Mahevas, M., Michel, M., Weill, J. C. & Reynaud, C. A. Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front. Immunol. 4, 494 (2013).
63. William, J., Euler, C., Christensen, S. & Shlomchik, M. J. Evolution of autoantibody responses via somatic hypermutation outside of germinal centers. Science 297, 2066-2070 (2002).
64. Groom, J. R. et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J. Exp. Med. 204, 1959-1971 (2007).
65. Jacobi, A. M. et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 48, 1332-1342 (2003).
66. Banchereau, R. et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell 165, 551-565 (2016).
67. Tipton, C. M. et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat. Immunol. 16, 755-765 (2015).
68. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603-607 (2002).
69. Hou, B. et al. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34, 375-384 (2011).
70. Nickerson, K. M. et al. TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J. Immunol. 184, 1840-1848 (2010).
71. Odegard, J. M. et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J. Exp. Med. 205, 2873-2886 (2008).
72. Lau, C. M. et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J. Exp. Med. 202, 1171-1177 (2005).
73. Christensen, S. R. et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J. Exp. Med. 202, 321-331 (2005).
74. Christensen, S. R. et al. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006).
75. Yasuda, K. et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J. Immunol. 178, 6876-6885 (2007).
76. Teichmann, L. L., Schenten, D., Medzhitov, R., Kashgarian, M. & Shlomchik, M. J. Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. Immunity 38, 528-540 (2013).
77. Thompson, J. S. et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293, 2108-2111 (2001).
78. He, B. et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat. Immunol. 11, 836-845 (2010).
79. von Bulow, G. U., van Deursen, J. M. & Bram, R. J. Regulation of the T-independent humoral response by TACI. Immunity 14, 573-582 (2001).
80. Figgett, W. A. et al. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. J. Autoimmun. 61, 9-16 (2015).
81. Jacobs, H. M. et al. Cutting edge: BAFF promotes autoantibody production via TACI-dependent activation of transitional B cells. J. Immunol. 196, 3525-3531 (2016).
82. Carter, L. M., Isenberg, D. A. & Ehrenstein, M. R. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum. 65, 2672-2679 (2013).
83. Cambridge, G. et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54, 723-732 (2006).
84. Daikeler, T. & Tyndall, A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract. Res. Clin. Haematol. 20, 349-360 (2007).
85. MacLennan, I. & Vinuesa, C. Dendritic cells, BAFF, and APRIL: innate players in adaptive antibody responses. Immunity 17, 235-238 (2002).
86. Vinuesa, C. G., Sanz, I. & Cook, M. C. Dysregulation of germinal centres in autoimmune disease. Nat. Rev. Immunol. 9, 845-857 (2009).
87. Wellmann, U. et al. The evolution of human anti-double-stranded DNA autoantibodies. Proc. Natl Acad. Sci. USA 102, 9258-9263 (2005).
88. Jackson, S. W. et al. Opposing impact of B cell-intrinsic TLR7 and TLR9 signals on autoantibody repertoire and systemic inflammation. J. Immunol. 192, 4525-4532 (2014).
89. Hua, Z. et al. Requirement for MyD88 signaling in B cells and dendritic cells for germinal center anti-nuclear antibody production in Lyn-deficient mice. J. Immunol. 192, 875-885 (2014).
90. Jackson, S. W. et al. B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6. J. Exp. Med. 213, 733-750 (2016).
91. Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6, 205-217 (2006).
92. Sullivan, K. E., Mullen, C. A., Blaese, R. M. & Winkelstein, J. A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J. Pediatr. 125, 876-885 (1994).
93. Crestani, E. et al. Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia. J. Allergy Clin. Immunol. 136, 1401-1404.e3 (2015).
94. Recher, M. et al. B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood 119, 2819-2828 (2012).
95. Lamagna, C., Hu, Y., DeFranco, A. L. & Lowell, C. A. B cell-specific loss of Lyn kinase leads to autoimmunity. J. Immunol. 192, 919-928 (2014).
96. Xu, Y., Harder, K. W., Huntington, N. D., Hibbs, M. L. & Tarlinton, D. M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 22, 9-18 (2005).
97. Harley, J. B. et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 40, 204-210 (2008).
98. Hom, G. et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med. 358, 900-909 (2008).
99. Lu, R. et al. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 10, 397-403 (2009).
100. Surolia, I. et al. Functionally defective germline variants of sialic acid acetylesterase in autoimmunity. Nature 466, 243-247 (2010).
101. Soni, C. et al. Distinct and synergistic roles of FcγRIIB deficiency and 129 strain-derived SLAM family proteins in the development of spontaneous germinal centers and autoimmunity. J. Autoimmun. 63, 31-46 (2015).
102. Bygrave, A. E. et al. Spontaneous autoimmunity in 129 and C57BL/6 mice-implications for autoimmunity described in gene-targeted mice. PLoS Biol. 2, E243 (2004).
103. Corneth, O. B. et al. Enhanced expression of Bruton's tyrosine kinase in B cells drives systemic autoimmunity by disrupting T cell homeostasis. J. Immunol. 197, 58-67 (2016).
104. Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572-2581 (2004).
105. Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221-232 (2010).
106. Pescovitz, M. D. et al. Rituximab, B-lymphocyte depletion, and preservation of β-cell function. N. Engl. J. Med. 361, 2143-2152 (2009).
107. Dahan, K. et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J. Am. Soc. Nephrol. 28, 348-358 (2016).
108. Ahmed, A. R., Spigelman, Z., Cavacini, L. A. & Posner, M. R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N. Engl. J. Med. 355, 1772-1779 (2006).
109. Hauser, S. L. et al. B-Cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
110. Beck, L. H. Jr et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J. Am. Soc. Nephrol. 22, 1543-1550 (2011).
111. Pendergraft, W. F. et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin. J. Am. Soc. Nephrol. 9, 736-744 (2014).
112. Cornec, D., Avouac, J., Youinou, P. & Saraux, A. Critical analysis of rituximab-induced serological changes in connective tissue diseases. Autoimmun. Rev. 8, 515-519 (2009).
113. Chan, O. T., Hannum, L. G., Haberman, A. M., Madaio, M. P. & Shlomchik, M. J. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189, 1639-1648 (1999).
114. Chan, O. & Shlomchik, M. J. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160, 51-59 (1998).
115. Wong, F. S. et al. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 53, 2581-2587 (2004).
116. Noorchashm, H. et al. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet β cells of nonobese diabetic mice. J. Immunol. 163, 743-750 (1999).
117. Molnarfi, N. et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J. Exp. Med. 210, 2921-2937 (2013).
118. Giles, J. R., Kashgarian, M., Koni, P. A. & Shlomchik, M. J. B cell-specific MHC class II deletion reveals multiple nonredundant roles for B cell antigen presentation in murine lupus. J. Immunol. 195, 2571-2579 (2015).
119. Wan, X., Thomas, J. W. & Unanue, E. R. Class-switched anti-insulin antibodies originate from unconventional antigen presentation in multiple lymphoid sites. J. Exp. Med. 213, 967-978 (2016).
120. Ehlers, M., Fukuyama, H., McGaha, T. L., Aderem, A. & Ravetch, J. V. TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. J. Exp. Med. 203, 553-561 (2006).
121. Soni, C. et al. B cell-intrinsic TLR7 signaling is essential for the development of spontaneous germinal centers. J. Immunol. 193, 4400-4414 (2014).
122. Walsh, E. R. et al. Dual signaling by innate and adaptive immune receptors is required for TLR7-induced B-cell-mediated autoimmunity. Proc. Natl Acad. Sci. USA 109, 16276-16281 (2012).
123. Shen, N. et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc. Natl Acad. Sci. USA 107, 15838-15843 (2010).
124. Garcia-Ortiz, H. et al. Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann. Rheum. Dis. 69, 1861-1865 (2010).
125. Kawasaki, A. et al. TLR7 single-nucleotide polymorphisms in the 3′ untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res. Ther. 13, R41 (2011).
126. Nickerson, K. M. et al. TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J. Immunol. 190, 1447-1456 (2013).
127. Han, J. W. et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat. Genet. 41, 1234-1237 (2009).
128. Gateva, V. et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 41, 1228-1233 (2009).
129. Vogelzang, A. et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29, 127-137 (2008).
130. Linterman, M. A. et al. IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J. Exp. Med. 207, 353-363 (2010).
131. Nurieva, R. I. et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 29, 138-149 (2008).
132. Bubier, J. A. et al. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc. Natl Acad. Sci. USA 106, 1518-1523 (2009).
133. Ozaki, K. et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173, 5361-5371 (2004).
134. Vinuesa, C. G. et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435, 452-458 (2005).
135. Dolff, S. et al. Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res. Ther. 13, R157 (2011).
136. Rankin, A. L. et al. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Faslpr/lpr/J mice. J. Immunol. 188, 1656-1667 (2012).
137. Bubier, J. A. et al. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. NY Acad. Sci. 1110, 590-601 (2007).
138. McPhee, C. G. et al. IL-21 is a double-edged sword in the systemic lupus erythematosus-like disease of BXSB.Yaa mice. J. Immunol. 191, 4581-4588 (2013).
139. Kopf, M., Herren, S., Wiles, M. V., Pepys, M. B. & Kosco-Vilbois, M. H. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J. Exp. Med. 188, 1895-1906 (1998).
140. Karnowski, A. et al. B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1. J. Exp. Med. 209, 2049-2064 (2012).
141. Poholek, A. C. et al. In vivo regulation of Bcl6 and T follicular helper cell development. J. Immunol. 185, 313-326 (2010).
142. Nurieva, R. I. et al. Bcl6 mediates the development of T follicular helper cells. Science 325, 1001-1005 (2009).
143. Linker-Israeli, M. et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol. 147, 117-123 (1991).
144. Jain, S. et al. Interleukin 6 accelerates mortality by promoting the progression of the systemic lupus erythematosus-like disease of BXSB.Yaa mice. PLoS ONE 11, e0153059 (2016).
145. Illei, G. G. et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 62, 542-552 (2010).
146. Vanden Bush, T. J. & Bishop, G. A. TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation. Eur. J. Immunol. 38, 400-409 (2008).
147. de Valle, E. et al. NFκB1 is essential to prevent the development of multiorgan autoimmunity by limiting IL-6 production in follicular B cells. J. Exp. Med. 213, 621-641 (2016).
148. Goenka, R. et al. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J. Exp. Med. 211, 45-56 (2014).
149. Wensveen, F. M., Slinger, E., van Attekum, M. H., Brink, R. & Eldering, E. Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling. Sci. Rep. 6, 35673 (2016).
150. Baechler, E. C. et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl Acad. Sci. USA 100, 2610-2615 (2003).
151. Bennett, L. et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
152. Kirou, K. A. et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 52, 1491-1503 (2005).
153. Deng, Y. & Tsao, B. P. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat. Rev. Rheumatol. 6, 683-692 (2010).
154. Kiefer, K., Oropallo, M. A., Cancro, M. P. & Marshak-Rothstein, A. Role of type I interferons in the activation of autoreactive B cells. Immunol. Cell Biol. 90, 498-504 (2012).
155. Haas, C., Ryffel, B. & Le Hir, M. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J. Immunol. 158, 5484-5491 (1997).
156. Schwarting, A., Wada, T., Kinoshita, K., Tesch, G. & Kelley, V. R. IFN-γ receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Faslpr mice. J. Immunol. 161, 494-503 (1998).
157. Lee, S. K. et al. Interferon-γ excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity 37, 880-892 (2012).
158. Domeier, P. P. et al. IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J. Exp. Med. 213, 715-732 (2016).
159. Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014-2021 (2016).
160. Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526-1533 (2003).
161. Pihoker, C., Gilliam, L. K., Hampe, C. S. & Lernmark, A. Autoantibodies in diabetes. Diabetes 54 (Suppl. 2), S52-S61 (2005).
162. Deane, K. D., Norris, J. M. & Holers, V. M. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum. Dis. Clin. North Am. 36, 213-241 (2010).
163. Sokolove, J. et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 7, e35296 (2012).
164. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02603146 (2017).
165. Qi, H. T follicular helper cells in space-time. Nat. Rev. Immunol. 16, 612-625 (2016).
166. Craft, J. E. Follicular helper T cells in immunity and systemic autoimmunity. Nat. Rev. Rheumatol. 8, 337-347 (2012).
167. Raj, T. et al. Common risk alleles for inflammatory diseases are targets of recent positive selection. Am. J. Hum. Genet. 92, 517-529 (2013).
168. Ramos, P. S., Shedlock, A. M. & Langefeld, C. D. Genetics of autoimmune diseases: insights from population genetics. J. Hum. Genet. 60, 657-664 (2015).
169. Gomez, L. M., Anaya, J. M. & Martin, J. Genetic influence of PTPN22 R620W polymorphism in tuberculosis. Hum. Immunol. 66, 1242-1247 (2005).
170. Clatworthy, M. R. et al. Systemic lupus erythematosus-associated defects in the inhibitory receptor FcγRIIb reduce susceptibility to malaria. Proc. Natl Acad. Sci. USA 104, 7169-7174 (2007).
171. Hartley, S. B. et al. Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature 353, 765-769 (1991).
172. Nemazee, D. Receptor editing in lymphocyte development and central tolerance. Nat. Rev. Immunol. 6, 728-740 (2006).
173. Cambier, J. C., Gauld, S. B., Merrell, K. T. & Vilen, B. J. B-Cell anergy: from transgenic models to naturally occurring anergic B cells? Nat. Rev. Immunol. 7, 633-643 (2007).
174. Gaudin, E. et al. Positive selection of B cells expressing low densities of self-reactive BCRs. J. Exp. Med. 199, 843-853 (2004).
175. Cyster, J. G. et al. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 381, 325-328 (1996).
176. Julien, S., Soulas, P., Garaud, J. C., Martin, T. & Pasquali, J. L. B cell positive selection by soluble self-antigen. J. Immunol. 169, 4198-4204 (2002).
177. Gu, H., Tarlinton, D., Muller, W., Rajewsky, K. & Forster, I. Most peripheral B cells in mice are ligand selected. J. Exp. Med. 173, 1357-1371 (1991).
178. Levine, M. H. et al. A B-cell receptor-specific selection step governs immature to mature B cell differentiation. Proc. Natl Acad. Sci. USA 97, 2743-2748 (2000).
179. Schiemann, B. et al. AN essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293, 2111-2114 (2001).
180. Richardson, C. et al. Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus. J. Immunol. 191, 4926-4939 (2013).
181. Jenks, S. A. et al. 9G4+ autoantibodies are an important source of apoptotic cell reactivity associated with high levels of disease activity in systemic lupus erythematosus. Arthritis Rheum. 65, 3165-3175 (2013).
182. Pascual, V. et al. Nucleotide sequence analysis of the V regions of two IgM cold agglutinins. Evidence that the VH4-21 gene segment is responsible for the major cross-reactive idiotype. J. Immunol. 146, 4385-4391 (1991).
183. Thompson, K. M. et al. Human monoclonal antibodies against blood group antigens preferentially express a VH4-21 variable region gene-associated epitope. Scand. J. Immunol. 34, 509-518 (1991).
184. Pugh-Bernard, A. E. et al. Regulation of inherently autoreactive VH4-34 B cells in the maintenance of human B cell tolerance. J. Clin. Invest. 108, 1061-1070 (2001).
185. Cappione, A. et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J. Clin. Invest. 115, 3205-3216 (2005).
186. Isenberg, D., Spellerberg, M., Williams, W., Griffiths, M. & Stevenson, F. Identification of the 9G4 idiotope in systemic lupus erythematosus. Br. J. Rheumatol. 32, 876-882 (1993).
187. Stevenson, F. K. et al. Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. J. Autoimmun. 6, 809-825 (1993).
188. van Vollenhoven, R. F. et al. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics. J. Rheumatol. 26, 1727-1733 (1999).